Amendments to the Specification:

The following amendments refer to the paragraph numbering in the published application, US 2007/0224658 A1.

Please amend the specification at paragraph **[0036]** as follows:

[0036] In a preferment, the amino acid sequence can comprise either or both of the Apo B binding site sequence(s) depicted below in the same peptide or in the form of dimers or in different peptides:

(1) Lys Ala Glu Tyr Lys Lys Asn Lys His Arg His (SEQ ID NO:1);
or

(2) Arg Leu Thr Arg Lys Arg Gly Leu Lys (SEQ ID NO:2);

and analogues thereof which are capable of binding to the Apo B100 receptor site.

Please amend Table 1 of the specification, located immediately following paragraph **[0061]**, as follows:

TABLE 1

Peptide	N-terminal	Sequence	C-terminal
1	Retinoic Acid	Leu-Arg-Leu-Thr-Arg-Lys-Arg-Gly-Leu-Lys-Leu (SEQ ID NO:3)	Cholesterol
2	Retinoic Acid	Gly-Thr-Thr-Arg-Leu-Thr-Arg-Lys-Arg-Gly-Leu-Lys-Leu- (SEQ ID NO:4)	-COOH

TABLE 1-continued

Peptide	N-terminal	Sequence	C-terminal
3	Retinoic Acid	~~Tyr-Lys-Leu-Glu-Gly-Thr-Thr-Arg-Leux-Thr-Arg-Lys-Arg-Gly-Leu-Lys-Leu-Ala-Thr-Ala Leu-Ser-~~ Tyr-Lys-Leu-Glu-Gly-Thr-Thr-Arg-Leu-Thr-Arg-Lys-Arg-Gly-Leu-Lys-Leu-Ala-Thr-Ala Leu-Ser- (SEQ ID NO:5)	Cholesterol
4	Pyrene Butyric Acid	Lys-Leu-Glu-Gly-Thr-Thr-Arg-Leu-Thr-Arg-Lys-Arg-Gly-Leu-Lys-Leu-Ala-Thr-Ala-Leu-Ser-Leu-Phe-Leu-Phe- (SEQ ID NO:6)	Cholesterol